01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
On October 2 the U.S Small Business Association (“SBA”) issued a Procedural Notice outlining the r...
Read More >
On January 31, 2020, U.S. Citizenship & Immigration Services (USCIS) announced the release of a new ...
Read More >
The amendments will become effective on January 4, 2021, with earlier compliance permitted. The ame...
Read More >
On October 10, 2019, Governor Newsom signed Assembly Bill 51 (AB 51) into law. This important legisl...
Read More >
On May 21, the Securities and Exchange Commission (SEC) adopted amendments to its rules governing fi...
Read More >
In early July, an appeals court ruled that Amazon should be considered a “seller” of goods under P...
Read More >